Skip to content

Jazz Pharmaceuticals JAZZ Effect of cross-border tax laws

Effect of cross-border tax laws at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$114.75K

Other financials

Income statement

See full
Revenue$1.1B+19.1%
Operating income$336.6M+702%
Net income$293.1M+417%
EPS (diluted)$4.43+391%

Balance sheet

See full
Cash & equivalents$667.5M-64.1%
Total debt$5.4B-0.1%
Total equity$4.5B+8.6%
Total assets$11.9B+2.8%

Cash flow

See full
Operating cash flow$408.2M-5.0%
CapEx$19.7M+41.7%
Free cash flow$388.5M-6.6%

Valuation

See full
Market cap$14.11B+54.4%
Enterprise value$18.85B+47.7%
P/S3.2×+0.9×

Profitability

See full
Operating margin-11.9%-28.1pp
Net margin-8.9%-20.5pp
FCF margin28.6%-8.6pp

Returns & leverage

See full
Return on equity-9.1%-21.2pp
Debt / equity1.2×-0.1×
Current ratio-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount.

The official record: Jazz Pharmaceuticals’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →

Ask your AI about Jazz Pharmaceuticals's effect of cross-border tax laws.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Jazz Pharmaceuticals's effect of cross-border tax laws?
Jazz Pharmaceuticals (JAZZ) reported effect of cross-border tax laws of $7.45M in Q4 2025.
What does effect of cross-border tax laws mean?
The tax impact resulting from international operations and cross-border tax laws.
How do you interpret effect of cross-border tax laws?
A benefit suggests favorable international tax treatment, while an expense indicates higher tax costs abroad.
How does effect of cross-border tax laws compare across companies?
Common for multinational corporations with significant non-domestic revenue streams.